HUE054495T2 - Rák kezelésére szolgáló készítmény - Google Patents

Rák kezelésére szolgáló készítmény

Info

Publication number: HUE054495T2
Authority: HU; Hungary
Prior art keywords: cancer; preparation; treatment
Prior art date: 2006-08-25

Application number

HUE12160586A

Other languages

English (en)

Inventor

Alan H Auerbach

Arie S Belldegrun

Original Assignee

Janssen Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-25

Filing date

2007-08-23

Publication date

2021-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054495(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-23 Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc

2021-09-28 Publication of HUE054495T2 publication Critical patent/HUE054495T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

HUE12160586A 2006-08-25 2007-08-23 Rák kezelésére szolgáló készítmény HUE054495T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US92150606P	2006-08-25	2006-08-25

Publications (1)

Publication Number	Publication Date
HUE054495T2 true HUE054495T2 (hu)	2021-09-28

Family

ID=38916904

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE12160586A HUE054495T2 (hu)	2006-08-25	2007-08-23	Rák kezelésére szolgáló készítmény

Country Status (21)

Country	Link
EP (3)	EP2061561B1 (hu)
JP (10)	JP2010501575A (hu)
KR (4)	KR20180003636A (hu)
CN (2)	CN101528308A (hu)
AU (6)	AU2007287098C1 (hu)
CA (1)	CA2661422C (hu)
CY (2)	CY1115477T1 (hu)
DK (2)	DK2478907T3 (hu)
ES (2)	ES2428634T3 (hu)
HK (1)	HK1131577A1 (hu)
HR (2)	HRP20130961T1 (hu)
HU (1)	HUE054495T2 (hu)
IL (3)	IL197211A0 (hu)
LT (1)	LT2478907T (hu)
NO (2)	NO20091190L (hu)
NZ (1)	NZ597830A (hu)
PL (2)	PL2061561T3 (hu)
PT (2)	PT2478907T (hu)
RS (2)	RS52956B (hu)
SI (2)	SI2478907T1 (hu)
WO (1)	WO2008024484A1 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
EP2061561B1 (en)	2006-08-25	2013-07-10	Cougar Biotechnology, Inc.	Compositions for treating cancer
WO2009009132A1 (en) *	2007-07-12	2009-01-15	Cougar Biotechnology, Inc.	Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
AR069079A1 (es) *	2007-10-29	2009-12-30	Takeda Pharmaceutical	Farmaco para la prevencion o el tratamiento de cancer
CN102558274B (zh) *	2010-12-08	2014-10-15	深圳万乐药业有限公司	一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) *	2010-12-20	2012-07-11	天津药物研究院	α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
WO2012097021A1 (en)	2011-01-11	2012-07-19	Glaxosmithkline Llc	Combination
MX2013011329A (es)	2011-04-01	2014-03-12	Genentech Inc	Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
US20120295932A1 (en) *	2011-05-17	2012-11-22	Western Connecticut Health Network, Inc.	Method for the treatment of cancer
CN103070828B (zh) *	2011-10-26	2016-01-27	山东新时代药业有限公司	一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) *	2011-10-31	2013-05-15	南京卡文迪许生物工程技术有限公司	醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) *	2012-05-04	2012-06-20	Jagotec Ag	Improvements in or relating to organic compounds
CA2872541A1 (en) *	2012-06-06	2013-12-12	Novartis Ag	Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
EA037806B1 (ru)	2012-09-26	2021-05-24	Арагон Фармасьютикалз, Инк.	Способ лечения неметастатического кастрационно-резистентного рака простаты
CN103800296A (zh) *	2012-11-13	2014-05-21	重庆医药工业研究院有限责任公司	一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) *	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
US20150246060A1 (en)	2013-03-15	2015-09-03	Iceutica Inc.	Abiraterone Acetate Formulation and Methods of Use
ES2986853T3 (es) *	2013-03-15	2024-11-13	Sun Pharmaceutical Ind Ltd	Formulación de acetato de abiraterona
KR20150138268A (ko) *	2013-04-04	2015-12-09	엑셀리시스, 인코포레이티드	암을 치료하기 위한 약물 병용요법
US20150157646A1 (en)	2013-09-27	2015-06-11	Iceutica Inc.	Abiraterone Steroid Formulation
EP3052098B1 (en) *	2013-10-01	2020-12-02	Novartis AG	Enzalutamide in combination with afuresertib for the treatment of prostate cancer
BR112016006976A2 (pt) *	2013-10-01	2017-08-01	Novartis Ag	combinação
CN104546745A (zh) *	2013-10-14	2015-04-29	深圳海王药业有限公司	醋酸阿比特龙的片剂组合物及其制备工艺
WO2016162229A1 (en) *	2015-04-10	2016-10-13	Capsugel Belgium N.V.	Abiraterone acetate lipid formulations
EP3490560B1 (en)	2016-07-29	2025-01-22	Janssen Pharmaceutica, N.V.	Niraparib for use in a method of treating prostate cancer
JOP20190244A1 (ar) *	2017-04-13	2019-10-13	Janssen Pharmaceutica Nv	تركيبة علاجية لسرطان البروستاتا
SG11202003402QA (en)	2017-10-16	2020-05-28	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) *	2017-10-30	2019-05-07	浙江京新药业股份有限公司	一种治疗前列腺癌的注射剂及其制备方法
CA3131034A1 (en)	2019-03-06	2020-09-10	Matthew J. Sharp	Abiraterone prodrugs
WO2021031991A1 (zh) *	2019-08-16	2021-02-25	中国科学院分子细胞科学卓越创新中心	治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
CN114560903B (zh) *	2022-03-09	2023-08-01	绍兴市上虞区武汉理工大学高等研究院	一种阿比特龙衍生物的制备方法及其细胞毒性评价

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2138618T3 (es)	1992-03-31	2000-01-16	Btg Int Ltd	Esteroides 17-sustituidos utiles en el tratamiento del cancer.
US5604213A (en)	1992-03-31	1997-02-18	British Technology Group Limited	17-substituted steroids useful in cancer treatment
AU4338501A (en) *	2000-03-02	2001-09-12	Univ Pittsburgh	Combination chemotherapy
WO2002053138A2 (en) *	2001-01-02	2002-07-11	Elisabeth Shanahan-Prendergast	Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
EP1556058B1 (en) *	2002-10-23	2007-12-12	Pantarhei Bioscience B.V.	Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US20050054620A1 (en) *	2003-01-13	2005-03-10	Koeffler H. Phillip	Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) *	2004-08-04	2006-02-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) *	2004-08-24	2004-09-29	Btg Int Ltd	Novel salt forms
EP2061561B1 (en)	2006-08-25	2013-07-10	Cougar Biotechnology, Inc.	Compositions for treating cancer

2007
- 2007-08-23 EP EP07837326.3A patent/EP2061561B1/en not_active Revoked
- 2007-08-23 SI SI200732177T patent/SI2478907T1/sl unknown
- 2007-08-23 KR KR1020177037293A patent/KR20180003636A/ko not_active Ceased
- 2007-08-23 EP EP12160586.9A patent/EP2478907B1/en not_active Revoked
- 2007-08-23 JP JP2009525647A patent/JP2010501575A/ja active Pending
- 2007-08-23 AU AU2007287098A patent/AU2007287098C1/en active Active
- 2007-08-23 CN CNA2007800385835A patent/CN101528308A/zh active Pending
- 2007-08-23 WO PCT/US2007/018769 patent/WO2008024484A1/en active Application Filing
- 2007-08-23 LT LTEP12160586.9T patent/LT2478907T/lt unknown
- 2007-08-23 ES ES07837326T patent/ES2428634T3/es active Active
- 2007-08-23 PL PL07837326T patent/PL2061561T3/pl unknown
- 2007-08-23 SI SI200731334T patent/SI2061561T1/sl unknown
- 2007-08-23 HU HUE12160586A patent/HUE054495T2/hu unknown
- 2007-08-23 KR KR1020097005974A patent/KR20090059126A/ko active Application Filing
- 2007-08-23 PT PT121605869T patent/PT2478907T/pt unknown
- 2007-08-23 CN CN201410261671.3A patent/CN104306977A/zh active Pending
- 2007-08-23 ES ES12160586T patent/ES2869343T3/es active Active
- 2007-08-23 RS RS20130401A patent/RS52956B/en unknown
- 2007-08-23 PT PT78373263T patent/PT2061561E/pt unknown
- 2007-08-23 KR KR1020157025243A patent/KR20150108946A/ko not_active Ceased
- 2007-08-23 RS RS20210531A patent/RS62034B1/sr unknown
- 2007-08-23 DK DK12160586.9T patent/DK2478907T3/da active
- 2007-08-23 KR KR1020207031218A patent/KR20200125776A/ko not_active Ceased
- 2007-08-23 NZ NZ597830A patent/NZ597830A/xx not_active IP Right Cessation
- 2007-08-23 EP EP20190748.2A patent/EP3804730A1/en not_active Withdrawn
- 2007-08-23 CA CA2661422A patent/CA2661422C/en active Active
- 2007-08-23 PL PL12160586T patent/PL2478907T3/pl unknown
- 2007-08-23 DK DK07837326.3T patent/DK2061561T3/da active
2009
- 2009-02-24 IL IL197211A patent/IL197211A0/en unknown
- 2009-03-20 NO NO20091190A patent/NO20091190L/no not_active Application Discontinuation
- 2009-11-06 HK HK09110386.2A patent/HK1131577A1/xx not_active IP Right Cessation
2011
- 2011-12-15 JP JP2011273983A patent/JP6053279B2/ja active Active
2013
- 2013-08-01 IL IL227746A patent/IL227746A0/en unknown
- 2013-08-20 CY CY20131100709T patent/CY1115477T1/el unknown
- 2013-10-10 HR HRP20130961TT patent/HRP20130961T1/hr unknown
2014
- 2014-12-17 JP JP2014254864A patent/JP2015110577A/ja active Pending
2015
- 2015-08-31 AU AU2015221447A patent/AU2015221447B9/en not_active Ceased
2016
- 2016-11-17 JP JP2016224393A patent/JP2017052791A/ja active Pending
2017
- 2017-03-15 AU AU2017201764A patent/AU2017201764A1/en not_active Abandoned
- 2017-12-20 JP JP2017243588A patent/JP6445123B2/ja active Active
2018
- 2018-02-22 IL IL257681A patent/IL257681A/en unknown
- 2018-11-28 JP JP2018222531A patent/JP2019059750A/ja not_active Withdrawn
- 2018-11-29 AU AU2018271331A patent/AU2018271331A1/en not_active Abandoned
2020
- 2020-03-27 JP JP2020057344A patent/JP6740497B2/ja active Active
- 2020-07-01 NO NO20200775A patent/NO20200775A1/no not_active Application Discontinuation
- 2020-11-20 JP JP2020193403A patent/JP2021038252A/ja not_active Withdrawn
2021
- 2021-03-16 AU AU2021201649A patent/AU2021201649A1/en not_active Ceased
- 2021-04-27 HR HRP20210670TT patent/HRP20210670T1/hr unknown
- 2021-06-10 CY CY20211100513T patent/CY1124221T1/el unknown
2022
- 2022-07-18 AU AU2022206696A patent/AU2022206696A1/en not_active Abandoned
- 2022-10-06 JP JP2022161610A patent/JP2022185091A/ja not_active Withdrawn
2024
- 2024-08-22 JP JP2024140948A patent/JP2024164147A/ja active Pending

Also Published As

Publication number	Publication date
WO2008024484A1 (en)	2008-02-28
RS52956B (en)	2014-02-28
DK2061561T3 (da)	2013-10-07
AU2015221447B9 (en)	2017-07-20
NO20091190L (no)	2009-03-20
EP2061561B1 (en)	2013-07-10
AU2018271331A1 (en)	2018-12-20
LT2478907T (lt)	2021-06-25
NZ597830A (en)	2013-02-22
JP2012082215A (ja)	2012-04-26
JP6053279B2 (ja)	2016-12-27
JP2024164147A (ja)	2024-11-26
JP2015110577A (ja)	2015-06-18
AU2021201649A1 (en)	2021-04-08
JP2020114851A (ja)	2020-07-30
JP2022185091A (ja)	2022-12-13
CN104306977A (zh)	2015-01-28
JP2021038252A (ja)	2021-03-11
ES2428634T3 (es)	2013-11-08
AU2007287098C1 (en)	2018-03-15
IL227746A0 (en)	2013-09-30
CA2661422C (en)	2017-06-27
AU2007287098A1 (en)	2008-02-28
KR20180003636A (ko)	2018-01-09
EP2478907A2 (en)	2012-07-25
PL2478907T3 (pl)	2021-10-25
EP2478907A3 (en)	2012-08-01
HRP20130961T1 (hr)	2013-11-22
HK1131577A1 (en)	2010-01-29
IL197211A0 (en)	2009-12-24
EP2061561A1 (en)	2009-05-27
ES2869343T3 (es)	2021-10-25
AU2017201764A1 (en)	2017-04-06
PT2478907T (pt)	2021-05-26
AU2007287098B2 (en)	2013-08-15
EP2478907B1 (en)	2021-04-14
KR20090059126A (ko)	2009-06-10
EP3804730A1 (en)	2021-04-14
JP6445123B2 (ja)	2018-12-26
RS62034B1 (sr)	2021-07-30
PT2061561E (pt)	2013-10-09
IL257681A (en)	2018-04-30
JP2010501575A (ja)	2010-01-21
NO20200775A1 (no)	2009-03-20
SI2061561T1 (sl)	2013-11-29
KR20200125776A (ko)	2020-11-04
DK2478907T3 (da)	2021-05-25
JP2019059750A (ja)	2019-04-18
JP6740497B2 (ja)	2020-08-12
JP2018065859A (ja)	2018-04-26
AU2022206696A1 (en)	2022-08-11
CY1115477T1 (el)	2017-01-04
PL2061561T3 (pl)	2013-12-31
AU2015221447A1 (en)	2015-09-17
HRP20210670T1 (hr)	2021-06-11
CN101528308A (zh)	2009-09-09
KR20150108946A (ko)	2015-09-30
JP2017052791A (ja)	2017-03-16
SI2478907T1 (sl)	2021-08-31
AU2015221447B2 (en)	2016-12-15
CY1124221T1 (el)	2022-05-27
CA2661422A1 (en)	2008-02-28

Publication	Publication Date	Title
HUE054495T2 (hu)	2021-09-28	Rák kezelésére szolgáló készítmény
IL248204A0 (en)	2016-11-30	Combined treatment of tumors expressing 38cd
HUS1600048I1 (hu)	2017-01-30	Készítmény Fabry-kór kezelésére
IL197217B (en)	2019-12-31	Novel anti-cd38 antibodies for the treatment of cancer
SMAP200900085A (it)	2010-01-19	3-imidazolil-indoli per il trattamento di malattieproliferative
DK2121139T3 (da)	2013-01-14	Formulations for cancer treatment
IL196470A (en)	2016-07-31	Antagonist antibody for cancer treatment
BRPI0821779A2 (pt)	2019-09-24	tratamento terapêutico de câncer
IL197315A0 (en)	2009-12-24	Treatment of cancer
BRPI0810206A2 (pt)	2014-10-21	Método de tratar câncer
ZA200808178B (en)	2010-11-24	Imidazolothiazole compounds for the treatment of disease
DK3289876T3 (da)	2022-10-10	Forbindelser til behandling af cancer
DK2056842T3 (da)	2013-01-14	Modificeret galactosylceramid til behandling af cancerøse sygdomme
EP2049139A4 (en)	2009-06-24	TREATMENT OF TUMORS EXPRESSING RAS
DK2154971T3 (da)	2012-04-02	Synergistisk farmaceutisk kombination til behandling af cancer
DK2035369T3 (da)	2014-10-06	Terapeutiske
BRPI0815551A2 (pt)	2015-02-18	Tratamento através de hucbc de doença beta-amiloide
DK2173831T3 (da)	2012-09-17	Brøndbehandling
ZA201003425B (en)	2011-04-28	5-cyano-thienopyridines for the treatment of tumors
BRPI0812932A2 (pt)	2014-12-09	Composições e métodos de tratar câncer
DK2147122T3 (da)	2014-10-13	Enzymatisk kræftbehandling
FI20095600L (fi)	2009-06-09	Koostumus ihosairauksien hoitoa varten
IL210066A0 (en)	2011-02-28	Novel ortho-aminoanilides for the treatment of cancer
BRPI0821100A2 (pt)	2017-05-23	composições e métodos para o tratamento de câncer de bexiga
BRPI0815051A2 (pt)	2015-02-10	Tratamento de tumores pediátricos